Application of proteomics technologies in the investigation of the brain

Mass Spectrometry Reviews

Volumn 23, Issue 4, 2004, Pages 231-258

  Fountoulakis, Michael ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Brain; Mass spectrometry; Neurological diseases; Proteomics; Two dimensional protein database

Indexed keywords

BIOMARKERS; DATABASE SYSTEMS; DISEASES; GENES; LIVING SYSTEMS STUDIES; MASS SPECTROMETRY; NEUROLOGY; PROTEINS;

NEUROLOGICAL DISEASES; PHENOTYPES; PROTEOMICS; TWO-DIMENSIONAL DATABASES;

BRAIN;

BIOLOGICAL MARKER; PROTEOME;

ANIMAL; BRAIN; HUMAN; METABOLISM; METHODOLOGY; PROTEOMICS; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; HUMANS; PROTEOME; PROTEOMICS;

EID: 3042554008     PISSN: 02777037     EISSN: None     Source Type: Journal    
DOI: 10.1002/mas.10075     Document Type: Review

References (150)

1. Aebersold R. 2003. Constellations in a cellular universe. Nature 422:115-116.
2. Aebersold R, Mann M. 2003. Mass spectrometry-based proteomics. Nature 422:198-207.
3. Alaiya AA, Franzén B, Auer G, Linder S. 2000. Cancer proteomics: From identification of novel markers to creation of artifical learning models for tumor classification. Electrophoresis 21:1210-1217.
4. Antonarakis SE. 1998. 10 Years of genomics, chromosome 21, and Down syndrome. Genomics 51:1-16.
5. Araki N, Morimasa T, Sakai T, Tokuoh H, Yunoue S, Kamo M, Miyazaki K, Abe K, Saya H, Tsugita A. 2000. Comparative analysis of brain proteins from p53-deficient mice by two-dimensional electrophoresis. Electrophoresis 21:1880-1889.
6. Bajo M, Fruehauf J, Kim SH, Fountoulakis M, Lubec G. 2002. Proteomic evaluation of intermediary metabolism enzyme proteins in fetal Down syndrome cerebral cortex. Proteomics 2:1539-1546.
7. Balcz B, Kirchner L, Cairns N, Fountoulakis M, Lubec G. 2001. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transm Suppl 61:193-202.
8. Banks RE, Dunn MJ, Hochstrasser DF, Sanchez J-C, Blackstock W, Pappin DJ, Selby PJ. 2000. Proteomics: New perspectives, new biomedical opportunities. Lancet 356:1749-1756.
9. Becamel C, Alonso G, Galeotti N, Demey E, Jouin P, Ullmer C, Dumuis A, Bockaert J, Marin P. 2002. Synaptic multiprotein complexes associated with 5-HT(2C) receptors: A proteomic approach. EMBO J 21:2332-2342.
10. Beranova-Giorgianni S, Pabst MJ, Russell TM, Giorgianni F, Goldowitz D, Desiderio DM. 2002. Preliminary analysis of the mouse cerebellum proteome. Brain Res Mol Brain Res 98:135-140.
11. Berndt P, Hobohm U, Langen H. 1999. Reliable automatic protein identification from matrix-assisted laser desorption/ ionization mass spectrometric peptide fingerprints. Electrophoresis 20:3521-3526.
12. Bernert G, Fountoulakis M, Lubec G. 2002. Manifold decreased protein levels of matrin 3, reduced motor protein HMP and hlark in fetal Down syndrome brain. Proteomics 2:1752-1757.
13. Bichsel VE, Liotta LA, Petricoin EF III. 2001. Cancer proteomics: From biomarker discovery to signal pathway profiling. Cancer J 7:69-77.
14. Bjellqvist B, Ek K, Righetti PG, Gianazza E, Görg A, Westermeier R, Postel W. 1982. Isoelectric focusing in immobilized pH gradients: Principle, methodology and some applications. J Biochem Biophys Methods 6:317-339.
15. Boguski MS, McIntosh MW. 2003. Biomedical informatics for proteomics. Nature 422:233-237.
16. Bradford M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
17. Cairns NJ. 1999. Neuropathology. J Neural Transm Suppl 57: 61-74.
18. Carboni L, Piubelli C, Righetti PG, Jansson B, Domenici E. 2002. Proteomic analysis of rat brain tissue: Comparison of protocols for two-dimensional gel electrophoresis analysis based on different solubilizing agents. Electrophoresis 23:4132-4141.
19. Cash P. 2000. Proteomics in medical microbiology. Electrophoresis 21:1187-1201.
20. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. 2002a. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxyl-terminal hydrolase L-1. Free Radic Med 33:562-571.
21. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. 2002b. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: Dihydropyrimidinase- related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82:1524-1532.
22. Chen W, Ji J, Zhao R, Ru B. 2002. Comparative proteome analysis of human temporal cortex lobes by two-dimensional electrophoresis and identification of selected common proteins. Neurochem Res 27:871-881.
23. Cheon MS, Fountoulakis M, Cairns NJ, Dierssen M, Herkner K, Lubec G. 2001a. Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease. J Neural Transm Suppl 61:281-288.
24. Cheon MS, Fountoulakis M, Dierssen M, Ferreres JC, Lubec G. 2001b. Expression profiles of proteins in fetal brain with Down syndrome. J Neural Transm Suppl 61:311-319.
25. Cheon MS, Kim SH, Yaspo ML, Blasi F, Aoki Y, Melen K, Lubec G. 2003a. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: Challenging the gene dosage effect hypothesis (Part I). Amino Acids 24:111-117.
26. Cheon MS, Bajo M, Kim SH, Claudio JO, Stewart AK, Patterson D, Kruger WD, Kondoh H, Lubec G. 2003b. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: Challenging the gene dosage effect hypothesis (Part II). Amino Acids 24:119-125.
27. Cheon MS, Kim SH, Ovod V, Kopitar Jerala N, Morgan JI, Hatefi Y, Ijuin T, Takenawa T, Lubec G. 2003c. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: Challenging the gene dosage effect hypothesis (Part III). Amino Acids 24:127-134.
28. Cordwell SJ, Nouwens AS, Walsh BJ. 2001. Comparative proteomics in bacterial pathogens. Proteomics 1:461-472.
29. Corthals GL, Wasinger VC, Hochstrasser DF, Sanchez J-C. 2000. The dynamic range of protein expression: A challenge for proteomic research. Electrophoresis 21:1104-1115.
30. Dahmen N, Jungblut PR, Fischer V, Schrank M, Reuss S, Rujescu D, Hiemke C. 2002. Detection of TOAD-64 in adult rat brain as revealed by two-dimensional protein gel electrophoresis followed by MALDI mass spectrometry possible modulatory effect of chronic haloperidol treatment. Prog Neuropsychopharmacol Biol Psychiatry 26:693-698.
31. de la Monte SM. 1999. Molecular abnormalities of the brain in Down syndrome: Relevance to Alzheimer's neurodegeneration. J Neural Transm Suppl 57:1-19.
32. Dodel RC, Hampel H, Du Y. 2003. Immuotherapy for Alzheimer's disease. Lancet Neurol 2:215-220.
33. Engidawork E, Lubec G. 2001. Protein expression in Down syndrome brain. Amino Acids 21:331-361.
34. Engidawork E, Lubec G. 2003. Molecular changes in fetal Down syndrome brain. J Neurochem 84:895-904.
35. Engidawork E, Juranville J-F, Fountoulakis M, Dierssen M, Lubec G. 2001. Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome. J Neural Transm Suppl 61:117-130.
36. Engidawork E, Gulesserian T, Fountoulakis M, Lubec G. 2003. Expression of hypothetical proteins in human fetal brain: Increased expression of hypothetical protein 28.5 kDa in Down syndrome, a clue for its tentative role. Mol Genet Metab 78:295-301.
37. Fountoulakis M. 2000. Two-dimensional electrophoresis. In: Encyclopedia of separation science, II/electrophoresis. London: Academic Press, pp 1356-1363.
38. Fountoulakis M. 2001. Proteomics: Current technologies and applications in neurological disorders and toxicology. Amino Acids 21:363-381.
39. Fountoulakis M, Cairns N, Lubec G. 1999a. Increased levels of 14-3-3 protein forms gamma and epsilon in the brain of patients with Down syndrome and Alzheimer's disease. J Neural Transm Suppl 57:323-335.
40. Fountoulakis M, Juranville J-F, Berndt P. 1997a. Large-scale identification of proteins of Haemophilus influenzae by amino acid composition analysis. Electrophoresis 18:2968-2977.
41. Fountoulakis M, Takács B, Langen H. 1998b. Two-dimensional map of basic proteins of Haemophilus influenzae. Electrophoresis 19:761-766.
42. Fountoulakis M, Takács M-F, Takács B. 1999b. Enrichment of low-abundance proteins of Haemophilus influenzae by hydrophobic interaction chromatography. J Chromatogr A 833:157-168.
43. Fountoulakis M, Gasser R. 2003. Proteomic analysis of the cell envelope fraction of Escherichia coli. Amino Acids 24:19-41.
44. Fountoulakis M, Juranville J-F. 2003. Enrichment of low-abundance brain proteins by preparative electrophoresis. Anal Biochem 313:267-282.
45. Fountoulakis M, Lahm H-W. 1998. Hydrolysis and amino acid composition analysis of proteins. J Chromatogr A 826:109-134.
46. Fountoulakis M, Langen H. 1997. Identification of proteins by matrix-assisted laser desorption ionization-mass spectrometry following in-gel digestion in low-salt, nonvolatile buffer and simplified peptide recovery. Anal Biochem 250:153-156.
47. Fountoulakis M, Schlaeger J. 2003. The mitochondrial proteins of the neuroblastoma cell line IMR 32. Electrophoresis 24:260-275.
48. Fountoulakis M, Suter L. 2002. Proteomic analysis of the rat liver. J Chromatogr B 782:197-218.
49. Fountoulakis M, Takács B. 1998. Design of protein purification pathways. Application to the proteome of Haemophilus influenzae using Heparin chromatography. Protein Expression Purification 14:113-119.
50. Fountoulakis M, Takács B. 2001. Effect of strong detergents and chaotropes on the protein detection in two-dimensional gels. Electrophoresis 22:1593-1602.
51. Fountoulakis M, Takács B. 2002. Enrichment and proteomic analysis of low-abundance bacterial proteins. Methods Enzymol 358:288-306.
52. Fountoulakis M, Langen H, Evers S, Gray C, Takács B. 1997b. Two-dimensional map of Haemophilus influenzae following protein enrichment by heparin chromatography. Electrophoresis 18:1193-1202.
53. Fountoulakis M, Juranville J-F, Röder D, Evers S, Berndt P, Langen H. 1998a. Reference map of the low-molecular-mass proteins of Haemophilus influenzae. Electrophoresis 19:1819-1827.
54. Fountoulakis M, Schuller E, Hardmeier R, Berndt P, Lubec G. 1999c. Rat brain proteins: Two-dimensional protein database and variations in the expression level. Electrophoresis 20:3572-3579.
55. Fountoulakis M, Berndt P, Boelsterli UA, Crameri F, Winter M, Albertini S, Suter L. 2000a. Two-dimensional database of mouse liver proteins. Changes in hepatic protein levels following treatment with acetaminophen or its non-toxic regioisomer 3-acetamidophenol. Electrophoresis 21:2148-2161.
56. Fountoulakis M, Hardmeier R, Schuller E, Lubec G. 2000b. Differences in the protein level between neonatal and adult brain. Electrophoresis 21:673-678.
57. Fountoulakis M, Hardmeier R, Höger H, Lubec G. 2001a. Post mortem changes in the level of brain proteins. Exp Neurology 167:86-94.
58. Fountoulakis M, Juranville J-F, Berndt P, Langen H, Suter L. 2001b. Two-dimensional database of mouse liver proteins. An update. Electrophoresis 22:1747-1763.
59. Fountoulakis M, de Vera M-C, Crameri F, Boess F, Gasser R, Albertini S, Suter L. 2002a. Modulation of gene and protein expression by carbon tetrachloride in the rat liver. Toxicol Appl Pharmacol 183:71-80.
60. Fountoulakis M, Juranville J-F, Dierssen M, Lubec G. 2002b. Proteomic analysis of the fetal brain. Proteomics 2:1547-1576.
61. Fountoulakis M, Juranville J-F, Tsangaris G, Suter L. 2003. Fractionation of liver proteins by preparative electrophoresis. Amino Acids (in press).
62. Freidl M, Gulesserian T, Lubec G, Fountoulakis M, Lubec B. 2001. Deterioration of the transcriptional, splicing and elongation machinery in the brain of fetal Down syndrome. J Neural Transm Suppl 61:47-58.
63. Fuentes J, Genesca L, Kingsbury T, Cunningham K, Perez-Riba M, Estivill X, de la Luna S. 2000. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum Mol Genet 9:1681-1690.
64. Gauss C, Kalkum M, Lowe M, Lehrach H, Klose J. 1999. Analysis of the mouse proteome. (I) Brain proteins: Separation by two-dimensional electrophoresis and identification by mass spectrometry and genetic variation. Electrophoresis 20:575-600.
65. Gozal E, Gozal D, Pierce WM, Thongboonkerd V, Scherzer JA, Sachleben LR Jr, Brittian KR, Guo SZ, Cai J, Klein JB. 2002. Proteomic analysis of CA1 and CA3 regions of rat hippocampus and differential susceptibility to intermittent hypoxia. J Neurochem 83:331-345.
66. Grant SC, Husi H. 2001. Proteomics of multiprotein complexes: Answering fundamental questions in neuroscience. Trends Biotechnol 19:49-54.
67. Greber S, Lubec G, Cairns N, Fountoulakis M. 1999. Decreased synaptosomal associated protein 25 levels in the brain of patients with Down syndrome and Alzheimer's disease. Electrophoresis 20:928-934.
68. Griffin TJ, Aebersold R. 2001. Advances in proteome analysis by mass spectrometry. J Biol Chem 276:45497-45500.
69. Gulesserian T, Engidawork E, Fountoulakis M, Lubec G. 2001. Antioxidant proteins in fetal brain. Superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome. J Neural Transm Suppl 61:71-84.
70. Gulesserian T, Engidawork E, Fountoulakis M, Lubec G. 2003. Decreased brain levels of Lupus La protein and increased U5 small ribonucleoprotein- specific 40 kDa protein in fetal Down syndrome. Cell Mol Biol 49:733-738.
71. Gygi SP, Rist B, Griffin TJ, Eng J, Aebersold R. 2002. Proteome analysis of low-abundance proteins using multidimensional chromatography and isotope-coded affinity tags. J Proteome Res 1:47-54.
72. Görg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R, Weiss W. 2000. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21:1037-1053.
73. Halpain S. 2000. Actin and the agile spine: How and why do dendritic spines dance? Trends Neurosci 23:141-146.
74. Hanash S. 2003. Disease proteomics. Nature 422:226-232.
75. Hartinger J, Stenius K, Hogemann D, Jahn R. 1996. 16-BAC/ SDS-PAGE: A two-dimensional gel electrophoresis system suitable for the separation of integral membrane proteins. Anal Biochem 240:126-133.
76. Henzel WJ, Billeci TM, Stults JT, Wong SC, Grimley C, Watanabe C. 1993. Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci USA 90:5011-5015.
77. Herbert B, Righetti PG. 2000. A turning point in proteome analysis: Sample prefractionation via multicompartment electrolyzers with isoelectric membranes. Electrophoresis 21:3639-3648.
78. Hochstrasser DF. 1997. Wilkins MR, Williams KL, Appel RD, Hochstrasser DF, editors. Proteome research: New frontiers in functional genetics Berlin: Springer Verlag, pp 187-219.
79. Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG. 2000. Proteomic analysis on NMDA receptor-adhesion protein signaling complexes. Nat Neurosci 3:661-669.
80. Jacobsen JS. 2002. Alzheimer's disease: An overview of current and emerging therapeutic strategies. Curr Top Med Chem 2:343-352.
81. Jain KK. 2002. Application of laser capture microdissection to proteomics. Methods Enzymol 356:157-167.
82. Jenkins LW, Peters GW, Dixon CE, Zhang X, Clark RS, Skinner JC, Marion DW, Adelson PD, Kochanek PM. 2002. Conventional and functional proteomics using large format two-dimensional gel electrophoresis 24 hours after controlled cortical impact in postnatal day 17 rats. J Neurotrauma 19:715-740.
83. Jiang L, Lindpaintner K, Li H-F, Gu N-F, He L, Langen H, Fountoulakis M. 2003. Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids 25:49-57.
84. Jungblut PR, Zimny-Arndt U, Zeindl-Eberhart E, Stulik J, Koupilova K, Pleissner K-P, Otto A, Müller E-C, Sokolowska-Köhler W, Grabher G, Stöffler G. 1999. Proteomics in human disease: Cancer, heart and infectious diseases. Electrophoresis 20:2100-2110.
85. Juranville JF, Poschl B, Oesterhelt G, Schoenfeld HJ, Fountoulakis M. 1998. Glycerol affects the quantification of aspartate and glutamate in acid-hydrolyzed proteins. Amino Acids 15:253-262.
86. Karlsson K, Cairns N, Lubec G, Fountoulakis M. 1999. Enrichment of human brain proteins by heparin chromatography. Electrophoresis 20:2970-2976.
87. Kennedy S. 2002. The role of proteomics in toxicology: Identification of biomarkers of toxicity by protein expression analysis. Biomarkers 7:269-290.
88. Kettman JR, Frey JR, Lafkovits I. 2001. Proteome, transcriptome and genome: Top down or bottom up analysis? Biomol Eng 18:207-212.
89. Kim SH, Cairns N, Fountoulakis M, Lubec G. 2001a. Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease. Neurosci Lett 300:41-44.
90. Kim SH, Cairns N, Fountoulakis M, Lubec G. 2001b. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl 61:223-235
91. Kim SH, Dierssen M, Ferreres JC, Fountoulakis M, Lubec G. 2001c. Increased protein levels of heterogeneous nuclear ribonucleoprotein A2/B1 in fetal Down syndrome brains. J Neural Transm Suppl 61:273-280.
92. Kim SH, Fountoulakis M, Dierssen M, Lubec G. 2001d. Decreased protein levels of complex I 30-kDa subunit in fetal Down syndrome brains. J Neural Transm Suppl 61: 109-116.
93. Kim SH, Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G. 2001e. The reduction of NADH: Ubiquinone oxidoreductase 24 and 75-kDa subunits in the brain of patients with Down syndrome and Alzheimer's disease. Life Sci 68: 2741-2750.
94. Kim SH, Fountoulakis M, Cairns N, Lubec G. 2002a. Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. Biochem Biophys Res Comm 296:970-975.
95. Kim SH, Krapfenbauer K, Cheon MS, Fountoulakis M, Cairns NJ, Lubec G. 2002b. Human brain cytosolic histamine-N-methyltransferase is decreased in Down syndrome and increased in Pick's disease. Neurosci Lett 321:169-172.
96. Kirchner SG, Kim SH, Fountoulakis M, Lubec G. 2002. Reduced levels of DEAD-box proteins DBP-RB and p72 in fetal Down syndrome brains. Neurochem Res 27:1141-1146.
97. Klose J. 1975. Protein mapping by combined isoelectric focusing and electrophoresis in mouse tissue. A novel approach to testing for induced point mutations in mammals. Human-genetik 26:231-243.
98. Klose J, Nock C, Herrmannm M, Stuhler K, Marcus K, Bluggel M, Krause E, Schalkwyk LC, Rastan S, Brown SD, Bussow K, Himmelbauer H, Lehrach H. 2002. Genetic analysis of the mouse brain proteome. Nat Genet 30:385-393.
99. Konig S, Schmidt O, Rose K, Thanos S, Besselmann M, Zeller M. 2003. Sodium dodecyl sulfate versus acid-labile surfactant gel electrophoresis: Comparative proteomic studies on rat retina and mouse brain. Electrophoresis 24:751-756.
100. Korolainen MA, Goldsteins G, Alafuzoff I, Koistinaho J, Pirttila T. 2002. Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis 23:3428-3433.
101. Krapfenbauer K, Fountoulakis M, Lubec G. 2003b. A rat brain protein expression map including cytosolic and enriched mitochondrial and microsomal fractions. Electrophoresis 24:1847-1870.
102. Krapfenbauer K, Berger M, Lubec G, Fountoulakis M. 2001a. Changes in the brain protein levels following administration of kainic acid. Electrophoresis 22:2086-2091.
103. Krapfenbauer K, Berger M, Lubec G, Fountoulakis M. 2001b. Kainic acid-induced changes in the level of low-abundance brain proteins. Eur J Biochem 268:3532-3537.
104. Krapfenbauer K, Yoo BC, Fountoulakis M, Mitrova E, Lubec G. 2002. Expression patterns of antioxidant proteins in the brain of patients with sporadic Creutzfeldt-Jacob disease. Electrophoresis 23:2541-2547.
105. Krapfenbauer K, Engidawork E, Cairns N, Fountoulakis M, Lubec G. 2003a. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res 967: 152-160.
106. Kyte J, Doolittle RF. 1982. A simple method for displaying the hydropathic character of a protein. J Mol Biol 157:105-132.
107. Lahm HW, Langen H. 2000. Mass spectrometry: A tool for the identification of proteins separated by gels. Electrophoresis 21:2105-2114.
108. Langen H, Röder D, Juranville J-F, Fountoulakis M. 1997. Effect of the protein application mode and the acrylamide concentration on the resolution of protein spots separated by two-dimensional gel electrophoresis. Electrophoresis 18: 2085-2090.
109. Langen H, Berndt P, Röder D, Cairns N, Lubec G, Fountoulakis M. 1999. Two-dimensional map of human brain proteins. Electrophoresis 20:907-916.
110. Langen H, Takács B, Evers S, Berndt P, Lahm HW, Wipf B, Gray C, Fountoulakis M. 2000. Two-dimensional map of the proteome of Haemophilus influenzae. Electrophoresis 21:411-429.
111. Lubec G, Krapfenbauer K, Fountoulakis M. 2003. Proteomics in brain research. Potential and limitations. Progress Neurobiol 69:193-211.
112. Lubec G, Labudova O, Cairns N, Berndt P, Langen H, Fountoulakis M. 1999a. Reduced aldehyde dehydrogenase levels in the brain of patients with Down syndrome. J Neural Tranam Suppl 57:21-40.
113. Lubec G, Labudova O, Cairns N, Fountoulakis M. 1999b. Increased glyceraldehyde 3-phosphate dehydrogenase levels in the brain of patients with Down syndrome. Neuroscience Lett 260:141-145.
114. Lubec G, Nonaka M, Krapfenbauer K, Gratzer M, Cairns N, Fountoulakis M. 1999e. Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl 57:161-177.
115. Mann M, Wilm M. 1994. Error-tolerant identification of peptides in sequence databases by peptide sequence tags. Anal Chem 66:4390-4399.
116. Mouledous L, Hunt S, Harcourt R, Harry JL, Williams KL, Gutstein HB. 2003. Proteomic analysis of immunostained, laser-capture microdissected brain samples. Electrophoresis 24:296-302.
117. O'Farrell PH. 1975. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250:4007-4021.
118. Ochi H, Horiuchi I, Araki N, Toda T, Araki T, Sato K, Murai H, Osoegawa M, Yamada T, Okamura K, Ogino T, Mizumoto K, Yamashita H, Saya H, Kira J. 2002. Proteomic analysis of human brain identifies alpha-enolase as a novel auto-antigen in Hashimoto's encephalopathy. FEBS Lett 528: 197-202.
119. Oppermann M, Cols N, Nyman T, Helin J, Saarinen J, Byman I, Toran N, Alaiya AA, Bergman T, Kalkkinen N, Gonzalez-Duarte R, Jornvall H. 2000. Identification of fetal brain proteins by two-dimensional gel electrophoresis and mass spectrometry comparison of samples from individuals with or without chromosome 21 trisomy. Eur J Biochem 267:4713-4719.
120. Pasinetti GM, Ho L. 2001. From cDNA microarrays to high-throughput proteomics. Implications in the search for preventive initiatives to slow the clinical progression of Alzheimer's disease dementia. Restor Neurol Neurosci 18:137-142.
121. Paulson L, Martin P, Persson A, Nilsson CL, Ljung E, Westman-Brinkmalm A, Eriksson PS, Blennow K, Davidsson P. 2003. Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats. J Neurosci Res 71:526-533.
122. Pearson WR, Lipman DJ. 1988. Improved tools for biological sequence comparison. Proc Natl Acad Sci USA 85:2444-2448.
123. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. 2002. Clinical proteomics: Translating benchside promise into bedside reality. Nat Rev Drug Discov 1:683-695.
124. Righetti PG, Castagna A, Herbert B. 2001. Prefractionation techniques in proteome analysis. Anal Chem 73:320A-326A.
125. Righetti PG, Castagna A, Herbert B, Reymond F, Rossier JS. 2003. Prefractionation techniques in proteome analysis. Proteomics 3:1397-1407.
126. Rohlff C. 2000. Proteomics in molecular medicine: Applications in central nervous systems disorders. Electrophoresis 21: 1227-1234.
127. Rohlff C, Southan C. 2002. Proteomic approaches to central nervous system disorders. Curr Opin Mol Ther 4:251-258.
128. Santoni V, Molloy M, Rabilloud T. 2000. Membrane proteins and proteomics: Un amour impossible? Electrophoresis 21:1054-1070.
129. Schägger H, von Jagow G. 1987. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166:368-379.
130. Shapiro BL. 1999. The Down syndrome critical region. J Neural Transm Suppl 57:41-60.
131. Simpson RJ, Dorow DS. 2001. Cancer proteomics: From signaling networks to tumor markers. Trends Biotechnol 19:S40-S48.
132. Skynner HA, Rosahl TW, Knowles MR, Salim K, Reid L, Cothliff R, McAllister G, Guest PC. 2002. Alterations of stress related proteins in genetically altered mice revealed by two-dimensional differential in-gel electrophoresis analysis. Proteomics 2:1018-1025.
133. Steiner S, Witzmann FA. 2000. Proteomics: Applications and opportunities in preclinical drug development. Electrophoresis 21:2099-2104.
134. Takács BJ. 2001. Protein purification: Theoretical and methodological considerations. In: Meyers RA, editor. Encyclopedia of analytical chemistry. Chichester: John Wiley & Sons Ltd. pp 5955-5970.
135. Tsuji T, Shiozaki A, Kohno R, Yoshizato K, Shimohama S. 2002. Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem Res 27:1245-1253.
136. Tyers M, Mann M. 2003. From genomics to proteomics. Nature 422:193-197.
137. Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G. 2001. Decreased brain levels of 2′,3′-cyclic nucleotide-3′-phosphodiesterase in Down syndrome and Alzheimer's disease. Neurobiol Aging 22:547-553.
138. Wang JH, Hewick RM. 1999. Proteomics in drug discovery. Drug Discov Today 4:129-133.
139. Weiss M, Manneberg M, Juranville J-F, Lahm H-W, Fountoulakis M. 1998. Effect of the hydrolysis method on the determination of amino acid composition of proteins. J Chromatogr 795:263-275.
140. Weitzdoerfer R, Fountoulakis M, Lubec G. 2002. Reduction of actin related protein complex 2/3 in fetal Down syndrome brain. Biochem Biophys Res Commun 293:836-841.
141. Weitzdoerfer R, Dierssen M, Fountoulakis M, Lubec G. 2001a. Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure. J Neural Transm Suppl 61:59-70.
142. Weitzdoerfer R, Stolzlechner D, Dierssen M, Ferreres J, Fountoulakis M, Lubec G. 2001b. Reduction of nucleoside diphosphate kinase B, Rab GDP-dissociation inhibitor beta and histidine triad nucleotide-binding protein in fetal Down syndrome brain. J Neural Transm Suppl 61:347-359.
143. Wilkins MR, Pasquali C, Appel RD, Ou K, Golaz O, Sanchez J-C, Yan JX, Gooley AA, Hughes G, Humphery-Smith I, Williams KL, Hochstrasser DF. 1996. From proteins to proteomes: Large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology 14:61-65.
144. Yoo BC, Cairns N, Fountoulakis M, Lubec G. 2001a. Synaptsomal-proteins beta-soluble N-ethylmaleimide-sensitive factor attachment protein (beta-SNAP), gamma (gamma-SNAP) and synaptotagmin I in the brain of patients with Down syndrome and Alzheimer's disease. Dement Geriatr Cogn Disord 12:219-225.
145. Yoo BC, Fountoulakis M, Cairns N, Lubec G. 2001b. Changes of voltage-dependent anion channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis 22:172-179.
146. Yoo BC, Fountoulakis M, Dierssen M, Lubec G. 2001c. Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down syndrome. Dysregulation of the T-complex protein 1. J Neural Transm Suppl 61:321-334.
147. Yoo BC, Kim SH, Cairns N, Fountoulakis M, Lubec G. 2001d. Deranged expression of molecular chaperones in brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 280:249-258.
148. Yoo BC, Vlkolinsky R, Engidawork E, Cairns N, Fountoulakis M, Lubec G. 2001e. Differential expression of molecular chaperons in the brain of patients with Down syndrome. Electrophoresis 22:1233-1241.
149. Zabel C, Chamrad DC, Priller J, Woodman B, Meyer HE, Bates GP, Klose J. 2002. Alterations in the mouse and human proteome caused by Huntington's disease. Mol Cell Proteomics 1:366-375.
150. Zheng PP, Kros JM, Sillevis-Smitt PA, Luider TM, Fn FM. 2003. Proteomics in primary brain tumors. Front Biosci 8:D451-D463.